Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
53 studies found for:    S1106
Show Display Options
Rank Status Study
1 Terminated S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: bendamustine hydrochloride;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: vincristine sulfate
2 Active, not recruiting Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
Conditions: Renal Cell Carcinoma;   Clear-cell Metastatic Renal Cell Carcinoma
Interventions: Biological: Nivolumab;   Biological: Pazopanib;   Drug: Sunitinib;   Biological: Ipilimumab
3 Recruiting A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: NY-ESO-1 157-165 (165V);   Drug: Nivolumab;   Biological: gp100:280-288 (288V);   Drug: Montanide ISA 51 vegetable grade (VG);   Drug: Ipilimumab;   Procedure: Apheresis Procedure
4 Recruiting XParTS: Capecitabine/Cisplatin(XP) for Recurrent Gastric Cancer
Condition: Gastric Cancer
Intervention: Drug: Capecitabine, Cisplatin
5 Recruiting A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children
Condition: Growth Hormone-Deficiency
Interventions: Drug: TV-1106;   Drug: somatropin
6 Completed
Has Results
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
Conditions: Unstable Angina;   Non ST Segment Elevation Myocardial Infarction
Interventions: Drug: fondaparinux background and standard dose UFH;   Drug: Fondaparinux background and low dose heparin;   Drug: Open label fondaparinux
7 Recruiting TR-701 FA vs Linezolid for the Treatment of Nosocomial Pneumonia
Condition: Pneumonia
Interventions: Drug: TR-701 FA IV;   Drug: Linezolid
8 Completed Growth Hormone Treatment of Children Born With Retarded Intrauterine Growth at Age 2-5 Years
Conditions: Foetal Growth Problem;   Small for Gestational Age
Intervention: Drug: somatropin
9 Unknown  Divalproex Sodium ER in Adult Autism
Condition: Autism
Intervention: Drug: Divalproex Sodium ER
10 Recruiting Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-Small Cell Lung Cancer
Conditions: Adenosquamous Lung Carcinoma;   Bronchioloalveolar Carcinoma;   Large Cell Lung Carcinoma;   Lung Adenocarcinoma;   Squamous Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer
Interventions: Radiation: External Beam Radiation Therapy;   Radiation: Image-Guided Adaptive Radiation Therapy;   Drug: Paclitaxel;   Drug: Carboplatin;   Radiation: Fludeoxyglucose F-18;   Procedure: Positron Emission Tomography;   Procedure: Computed Tomography;   Other: Laboratory Biomarker Analysis
11 Completed
Has Results
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Conditions: Heart Failure;   Anemia;   Cardiovascular Disease;   Ventricular Dysfunction;   Congestive Heart Failure
Interventions: Drug: Darbepoetin alfa;   Drug: Placebo
12 Completed
Has Results
A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines
Condition: Heart Failure
Intervention: Drug: Eplerenone
13 Completed A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome
Condition: Coronary Heart Disease
Interventions: Drug: dalcetrapib;   Drug: Placebo;   Drug: Evidence-based medical care for Acute Coronary Syndrome
14 Completed The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial
Condition: Acute Coronary Syndrome
Interventions: Drug: Darapladib 160 mg;   Drug: Placebo;   Other: Standard Therapy
15 Completed
Has Results
Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure
Conditions: Acute Decompensated Heart Failure;   Congestive Heart Failure
Interventions: Drug: Aliskiren;   Drug: Placebo
16 Recruiting Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
Condition: Chronic Heart Failure With Reduced Ejection Fraction.
Intervention: Drug: LCZ696
17 Completed This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure
Condition: Heart Failure With Reduced Ejection Fraction
Interventions: Drug: LCZ696 200 mg BID;   Drug: Enalapril 10 mg BID
18 Recruiting Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF
Condition: Acute Heart Failure
Interventions: Drug: RLX030;   Drug: Placebo
19 Recruiting ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)
Condition: Acute Coronary Syndrome
Interventions: Drug: alirocumab SAR236553 (REGN727);   Other: placebo
20 Terminated Phase III Acute Coronary Syndrome
Condition: Acute Coronary Syndrome
Interventions: Drug: Apixaban;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years